
Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis
- After seven years as President of NIBR and a member of the ECN, Dr. Bradner will pursue a next chapter of scientific contribution and leadership outside of Novartis
- Building on NIBR foundation, Dr. Marshall to shape next era of biomedical innovation and continue Novartis leadership in R&D
Basel, September 1, 2022 — Novartis today announced that James (Jay) E. Bradner, M.D., will step down from the Executive Committee of Novartis (ECN), effective October 31st after seven years leading research at Novartis. Fiona H. Marshall, Ph.D., currently Senior Vice President and Global Head of Discovery Sciences, Preclinical Development and Translational Medicine at MSD (Merck & Co., Inc in USA), has been appointed as President of the Novartis Institutes for BioMedical Research (NIBR), effective November 1st, 2022 reporting to Vas Narasimhan, M.D., CEO of Novartis. Dr. Marshall will become a member of the ECN.
“Leading NIBR has been a privilege for which I will forever be grateful,” Jay Bradner said. “I am so proud of the medicines we have imagined together, and I am confident that Fiona and our leaders will continue the creative, productive and important research to the definitive benefit of those with life-threatening diseases.”
Vas Narasimhan said: “I am deeply grateful to Jay for his invaluable contributions to reimagining how we discover innovative medicines, recruiting world-class scientific leaders and expanding our collaborations with leading biotech companies and academic institutions. I wish him the very best in his future endeavors and am grateful Jay has agreed to assist with the transition.”
“I am delighted to welcome Fiona to Novartis. She is both an esteemed biomedical scientist and an accomplished biopharmaceuticals research leader. Her three decades of experience leading drug discovery and early development across large biopharma, biotech and academia and her deep passion for biomedical science make her the ideal leader to help us strengthen our innovation pipeline and advance future waves of high-value medicines.”
Fiona Marshall said: “I am very excited to join Novartis and lead the discovery teams who are renowned for their collaborative research and use of cutting-edge technologies. I look forward to working with them, colleagues across Novartis and our partners across the biopharma ecosystem to accelerate the translation of scientific discoveries into breakthrough medicines that address critical areas of unmet need for patients.”
Prior to joining Merck in 2018, Dr. Marshall was a Founder and Chief Scientific Officer of Heptares Therapeutics, a successful UK Biotech company focused on structure-based drug design that was subsequently acquired by the Japanese biotech company Sosei, where she continued to serve as Chief Scientific Officer. Earlier in her career, Dr. Marshall was Director of Molecular Pharmacology at Millennium Pharmaceuticals and spent 10 years at GSK, holding senior positions in Molecular Pharmacology and Neuroscience. She holds a BSc in Biochemistry from University of Bath (UK) and Ph.D. in Neuroscience from University of Cambridge (UK). Dr. Marshall is the recipient of the 2012 WISE Women of Outstanding Achievement for Innovation and Entrepreneurship Award, and the 2015 RSC Malcolm Campbell Award for chemistry and the Vane Medal from the British Pharmacological Society. She is a Fellow of the Royal Society and the Academy of Medical Sciences, Honorary Fellow of the British Pharmacological Society and Honorary Fellow of the Royal Society of Chemistry.
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “appoints,” “will,” “next chapter,” “to shape,” “next era,” “confident,” “wish,” “pipeline,” “advance,” “future waves,” “look forward,” “to accelerate,” or similar terms, or by express or implied discussions regarding the potential impact of Dr. Bradner's departure and of Dr. Marshall's experience, credentials, and future leadership on Novartis. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Dr. Bradner's departure and Dr. Marshall's appointment will have any particular impact on NIBR or Novartis, or that NIBR or Novartis will be successful in the future. In particular, our expectations could be affected by, among other things: the uncertainties inherent in research and development, including unexpected research or clinical trial results and additional analysis of existing data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com
# # #
Novartis Media Relations
E-mail: media.relations@novartis.com
Sreejit Mohan Global Head, Corporate Brand Strategy & External Engagement + 1 857 262 3178 sreejit.mohan@novartis.com Kara Cournoyer Head, NIBR Communications + 1 617 710 5447 kara.cournoyer@novartis.com | Richard Jarvis Head, Strategy & Financial Communications + 41 79 584 2326 richard.jarvis@novartis.com |
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Central | North America | ||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 345 4440 |
Nicole Zinsli-Somm | +41 61 324 3809 | Alina Levchuk | +1 862 778 3372 |
Isabella Zinck | +41 61 324 7188 | Parag Mahanti | +1 973-876-4912 |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release
Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a
DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release
Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68
Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release
Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.
Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release
AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us
Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release
VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin